Abstract
Notes
Ethics Statement
This study was approved by the Institutional Review Board of Asan Medical Center (IRB 2020-0364). Formal written informed consent was not required, with a waiver from the appropriate Institutional Review Board.
Author Contributions
Conceptualization: CSP. Data curation: HL. Formal analysis: HL. Funding acquisition: CSP. Investigation: CSP. Methodology: HL. Resources: WCH. Supervision: CSP. Validation: CSP, HL. Writing—original draft: HL. Writing— review & editing: CSP. Approval of final manuscript: all authors.
References
Table 1
Case No. | Study | Year | Age (yr) | Sex | Site | Clinical diagnosis | Size (cm) | Treatment | F/U period | Prognosis | Positive IHC | Negative IHC | Comments |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | Current case | 2020 | 33 | M | Lower extremity (Rt. knee) | Epidermal cyst | 2.0 | Excision | 8 mo | NROMD | S100 (diffuse, luminal component; patchy, solid component), EMA (patchy, luminal component; diffuse, solid component), CK7, CK5/6 (patchy), CD117 (patchy), EpCAM (patchy), CEA (intra-luminal), p63 (rare) | CK20, GCDFP-15, ER, calponin, SMA |
History of intracranial hemorrhage due to arteriovenous malformation No evidence of other malignancies |
2 | Requena et al. [1] | 1998 | NA | NA | Lower extremity | NA | NA | Excision | NA | NA | NA | NA |
First description Reported as mainly women with a mean age of 44 years (range, 20 to 55) Two cases of recurrent tumor after incomplete excision |
3 | NA | NA | Lower extremity | NA | NA | Excision | NA | NA | NA | NA | |||
4 | NA | NA | Lower extremity | NA | NA | Excision | NA | NA | NA | NA | |||
5 | NA | NA | Upper extremity | NA | NA | Excision | NA | NA | NA | NA | |||
6 | NA | NA | Pubis | NA | NA | Excision | NA | NA | NA | NA | |||
7 | Adamski et al. [5] | 2005 | 37 | M | Lower extremity (Lt. popliteal fossa) | NA | 2.0 | Excision | 2 yr | NROMD | CK7 | CK20, GCDFP-15, S100 | - |
8 | Fernandez-Flores et al. [4] | 2007 | 62 | F | Lower extremity (Lt. popliteal fossa) | NA | 0.8 | Excision | NA | NROMD | CK AE1/AE3, CAM 5.2, CK7, EMA, ER (2+, 1%–5% cells), c-erbB-2 (2+, 50%–75% cells), p53 (1+, 1%–5% cells), S100 (2+, 50%–75% cells) | CK20, CEA, PR, GCDFP-15, CD15, SMA | - |
9 | Rutten et al. [2] | 2009 | 48 | M | Lower extremity (Rt. thigh) | Dermatofibroma (histiocytoma) | - | Excision | 18 yr | NROMD | CK MNF116, CK AE1/AE3, CAM 5.2, CK7, CEA (more prominent in the ductal structures), EMA (more prominent in the ductal structures) | CK20, GCDFP-15, S100, α-SMA, MSA, calponin, CD68, vimentin | - |
10 | 51 | F | Upper extremity (Rt. forearm) | Cyst | - | Excision | NA | NA | - | ||||
11 | 44 | F | Back | Dermatofibroma (histiocytoma) | - | Excision | 13 yr | NROMD | - | ||||
12 | 77 | F | Neck | NA | - | Excision | NA | NA | Recurrent tumor after incomplete excision | ||||
13 | 32 | F | Lower extremity (Rt. thigh) | Dermatofibroma (histiocytoma) | - | Excision | 9 yr | NROMD | - | ||||
14 | 42 | F | Lower extremity (Rt. thigh) | Dermatofibroma (histiocytoma) | - | Excision | NA | NA | - | ||||
15 | 34 | F | Upper extremity (Rt. arm) | Dermatofibroma (histiocytoma) | - | Excision | 11 yr | NROMD | - | ||||
16 | 40 | M | Upper extremity (Lt. forearm) | Dermatofibroma (histiocytoma) | - | Excision | NA | NA | - | ||||
17 | 23 | M | Lower extremity (Lt. calf) | NA | - | Excision | NA | NA | - | ||||
18 | 20 | F | Rt. buttock | Cyst | - | Excision | NA | NA | No evidence of other malignancies | ||||
19 | 67 | F | Lt. preauricular area | BCC vs. adnexal tumor | - | Excision | 8 yr | NROMD | - | ||||
20 | 60 | M | Lower extremity (Rt. foot dorsum) | Dermatofibroma (histiocytoma) | - | Excision | 4 yr | NROMD | - | ||||
21 | 54 | F | Upper extremity (acral) | NA | - | Excision | NA | NA | - | ||||
22 | 49 | F | Lower extremity (Lt. thigh) | Dermatofibroma (histiocytoma) | - | Excision | 4 yr | NROMD | - | ||||
23 | 59 | F | Lt. shoulder | Dermatofibroma (histiocytoma) | - | Excision | NA | NA | - | ||||
24 | 28 | M | Lower extremity (Rt. lower leg) | NA | - | Excision | NA | NA | - | ||||
25 | 54 | M | Upper extremity (Rt. hand) | NA | - | Excision | NA | NA | - | ||||
26 | 50 | F | Upper extremity (Rt. hand) | NA | - | Excision | NA | NA | - | ||||
27 | 70 | M | Rt. trunk | Long-standing lesion | - | Excision | 6 yr | NROMD | - | ||||
28 | 64 | F | NA | Dermatofibroma (histiocytoma) | - | Excision | 5 yr | NROMD | - | ||||
29 | 40 | F | Lower extremity (Lower arm) | NA | - | Excision | 5 yr | NROMD | - | ||||
30 | 64 | M | Upper back | Dermatofibroma (histiocytoma) or cyst | - | Excision | 3 yr | NROMD | - | ||||
31 | 54 | M | Lower extremity (Lower arm) | NA | - | Excision | 3 yr | NROMD | - | ||||
32 | 44 | F | Upper extremity (Lt. thumb) | NA | - | Excision | 2 yr | NROMD | - | ||||
33 | 36 | F | Lower extremity (Lt. anterior thigh) | Dermatofibroma (histiocytoma) | - | Excision | NA | NA | - | ||||
34 | 26 | F | Lower extremity (Lt. posterior leg) | Fibroma | - | Excision | NA | NA | - | ||||
35 | Arps et al. [3] | 2015 | 41 | F | Lower extremity (leg) | Epidermal inclusion cyst | 0.6 | Excision | NA | NROMD | S100 (diffuse in three cases, patchy in one case), CD117 (diffuse in two cases, patchy in one case), CK5/6, CK7, EpCAM, CEA (luminal), EMA (luminal), p63 (rare) | CK20, GCDFP-15, ER, PR, calponin, SMA | - |
36 | 32 | F | Upper extremity (elbow) | NA | 0.5 | Excision | NA | NA | - | ||||
37 | 35 | M | Lower extremity (leg) | NA | 0.5 | Excision | NA | NROMD | - | ||||
38 | 59 | F | Upper extremity (arm) | NA | 0.4 | Excision | NA | NA | - | ||||
39 | 61 | M | Upper extremity (arm) | Mobile nodule | 0.7 | Excision | NA | NA | - | ||||
40 | 31 | M | Lower extremity (leg) | Dermatofibroma | 1.2 | Excision | NA | NA | - | ||||
41 | Yokota et al. [7] | 2017 | 39 | F | Upper extremity (Rt. forearm) | NA | 0.5 (clinical) | Excision | 15 mo | NROMD | CK5/6, CK7, CA15-3, CA125, CD117, S100 (partially), p53 (partially), p63 (partially) | CK20, calponin, GCDFP-15, mammaglobulin, MUC1, ER, AR, D2–40 | Stable in size for more than 10 years, no evidence of other malignancies |
42 | Bogner et al. [6] | 2018 | 65 | M | Lt. lateral neck | NA | 0.6 (clinical) | Excision | 3 mo | NROMD | CK7 (strong), EMA (strong), CAM 5.2 (strong), EpCAM (lesser degree), CEA (in some of the lumina), p63, p40 | CK20, D2–40, TTF-1, CDX-2, hepatocyte antigen, PSA, PSAP, calponin, S100 | No evidence of other malignancies |
F/U, follow up; IHC, immunohistochemical staining; Rt., right; Lt., left; NROMD, no recurrence or metastatic disease; EMA, epithelial membrane antigen; CK, cytokeratin; EpCAM, epithelial cell adhesion molecule; CEA, carcinoembryonic antigen; GCDFP-15, gross cystic disease fluid protein-15; ER, estrogen receptor; SMA, smooth muscle actin; MSA, muscle specific antigen; NA, data not available; S100, S-100 protein; PR, progesterone receptor; BCC, basal cell carcinoma; MUC1, mucin1; AR, androgen receptor; TTF-1, thyroid transcription factor 1; PSA, prostate-specific antigen; PSAP, prostatic acid phosphatase; +, >50% of tumor cells are positive; patchy, 25%–50% of tumor cells are positive; rare, < 1% of tumor cells are positive.
Table 2
Cribriform carcinoma | Adenoid cystic carcinoma | Secretory carcinoma | Tubular adenoma | |
---|---|---|---|---|
Architecture |
Usually well-circumscribed Mixed variable portion of solid and cribriform |
Poorly circumscribed Composed of lobules, islands, and cords of basaloid cells with numerous cystic and ductular spaces |
Intradermal, circumscribed Back-to-back proliferation of tubules and microcysts |
Well circumscribed Variable sized tubules with attenuated epithelium |
No back-to-back appearance | Cuboidal cells | Micro-papillae, and focal intraluminal bridging | ||
No cuboidal cells | Sclerotic stroma | Paucicellular fibrous stroma | ||
Desmoplastic stroma | Recognition of myoepithelial layer | |||
Intra-(pseudo) luminal substance | Eosinophilic substance with PAS reaction | Mucin or basement membrane material that stains with mucicarmine, Alcian blue, and colloidal iron | Conspicuous intraluminal secretions | Eosinophilic proteinaceous material |
Nuclei | Pleomorphic | Uniform | Mildly pleomorphic | Uniform |
Mitosis | Rare | Rare | Rare to few | Absent |
Perineural invasion | Absent | Present, frequent | Absent | Absent |
Immunohistochemical staining | Variable CK (MNF116, AE1/AE3, CAM5.2, and CK7) | EMA and monoclonal CEA | S100 protein, mammaglobin and STAT5A | HMFG-1 and GCDFP-15 |
EpCAM | S100, p63, GFAP, SMA, MSA and calponin: often stain peripheral cells (myoepithelial differentiation) | NTRK3: variable | EMA and CEA: luminal cells | |
CD117, S100, and p63: variable | S100 and SMA: myoepithelial cells | |||
CEA, EMA: highlight ductal component | ||||
Reference | [11,12] | [12,13] | [12,14] | [3,12,13] |
PAS, periodic acid-Schiff; CK, cytokeratin; EMA, epithelial membrane antigen; CEA, carcinoembryonic antigen; S100, S-100 protein; GCDFP-15, gross cystic disease fluid protein-15; EpCAM, epithelial cell adhesion molecule; GFAP, glial fibrillary acidic protein; SMA, smooth muscle actin; MSA, muscle specific antigen.